CN Patent

CN109053616B — 前列腺特异性膜抗原(psma)的标记的抑制剂及其用途

Assigned to Novartis AG · Expires 2022-08-19 · 4y expired

What this patent protects

本申请提供前列腺特异性膜抗原(PSMA)的标记的抑制剂及其用途。本发明总体上涉及放射药剂的领域和它们在核医学中作为示踪物、显影剂和用于治疗各种前列腺癌的疾病状态的用途。因此，本发明涉及由通式(1a)或(1b)表示的化合物。

USPTO Abstract

本申请提供前列腺特异性膜抗原(PSMA)的标记的抑制剂及其用途。本发明总体上涉及放射药剂的领域和它们在核医学中作为示踪物、显影剂和用于治疗各种前列腺癌的疾病状态的用途。因此，本发明涉及由通式(1a)或(1b)表示的化合物。

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: CN109053616B
Jurisdiction: CN
Classification: —
Expires: 2022-08-19
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.